1 Β· Quick Reference
Before you start: indication confirmed Β· consent obtained Β· focused history/airway assessment done Β· fasting status noted (does not itself delay sedation β section 2) Β· monitoring attached Β· team roles assigned Β· time-out performed
β
Monitoring (continuous): SpOβ Β· respiratory rate/pattern Β· blood pressure Β· ECG/heart rate Β· capnography (strongly recommended for moderate/deep sedation) Β· level of sedation, from before the first dose until back to baseline
β
Common adult starting doses (titrate to effect β see full drug table in section 5): ketamine 1β1.5 mg/kg IV or 4 mg/kg IM Β· propofol 0.5β1 mg/kg IV (10β20 mg increments if elderly/frail) Β· midazolam 1β2 mg IV (0.5 mg if elderly/frail) Β· fentanyl up to 1 mcg/kg IV
β
Sedation emergency, in order: Recognise β Stop/reduce further drug β Airway manoeuvres + 100% Oβ β Support ventilation (BVM) β Reversal agent if opioid/benzodiazepine-related β Escalate/call for help and resuscitate
β
Safe discharge needs ALL of: back to baseline mental status and vital signs Β· protective airway reflexes intact Β· pain and nausea controlled Β· no unresolved sedation-related concern Β· responsible adult present if going home (see section 10)
2 Β· Patient Assessment Before Sedation
- Indications: any painful, anxiety-provoking or immobility-requiring ED procedure where analgesia alone is insufficient β e.g. fracture/dislocation reduction, cardioversion, abscess incision and drainage, complex wound care, imaging requiring stillness
- Absolute/relative contraindications: inability to obtain consent (and no valid best-interests/emergency basis), lack of appropriately trained/available staff or equipment, anticipated difficult airway without a clear back-up plan, unstable cardiorespiratory status, and any specific drug contraindication (see section 5)
- Focused history: indication and urgency of the procedure Β· allergies Β· current medications and relevant comorbidities (cardiac, respiratory, hepatic/renal disease, obstructive sleep apnoea) Β· previous anaesthetic/sedation problems Β· alcohol and recreational drug use Β· last oral intake (food and fluids) Β· pregnancy status where relevant
- Fasting status: current emergency medicine guidance does not support delaying procedural sedation based on fasting time alone β there is no demonstrated reduction in aspiration/vomiting risk from waiting, and any delay must be weighed against the clinical need for the procedure
- ASA physical status: ASA I β normal healthy patient Β· ASA II β mild systemic disease Β· ASA III β severe systemic disease Β· ASA IV β severe systemic disease that is a constant threat to life Β· ASA V β moribund, not expected to survive without the procedure. Many departments treat ASA III or above as a trigger to involve a senior/anaesthetic colleague or reconsider the setting rather than an absolute exclusion β follow local policy
- Airway assessment (LEMON): Look β beard, dentition, obesity, trauma, cachexia; Evaluate 3-3-2 (mouth opening, mentum-hyoid, hyoid-thyroid distances); Mallampati score (class IIIβIV β anticipate a difficult airway); Obstruction β swelling, trauma, foreign body, fat; Neck mobility
- Cardiopulmonary assessment: baseline auscultation, exercise tolerance, known cardiac/respiratory disease, and risk factors for difficult bag-mask ventilation or intubation
- Baseline observations: heart rate, blood pressure, respiratory rate, SpOβ and, where indicated, an ECG before starting
- Investigations: only when clinically indicated by history/comorbidity (e.g. ECG for known cardiac disease, blood glucose in diabetic patients) β procedural sedation does not require routine bloods
- When to involve anaesthesia/senior support or reconsider an alternative approach: anticipated or known difficult airway, Mallampati IIIβIV, ASA III or above, significant cardiorespiratory disease, morbid obesity with OSA, or any case where the sedating clinician is not confident managing a potential airway/cardiovascular complication alone
3 Β· Before Sedation Checklist
- Location and staffing: a resuscitation-capable area with a minimum of a sedating practitioner (not also performing the procedure), a practitioner performing the procedure, and a dedicated member of nursing staff solely responsible for monitoring
- IV access secured and working
- Oxygen and delivery devices available and connected
- Suction on, tested and immediately to hand
- Bag-valve-mask of the correct size, connected to oxygen
- Airway adjuncts (oropharyngeal/nasopharyngeal airways, supraglottic device) available
- Full intubation/resuscitation equipment and drugs immediately available, including a difficult-airway trolley
- Defibrillator in the room or immediately available
- Reversal agents (naloxone, flumazenil) drawn up or immediately accessible where opioids/benzodiazepines are being used
- Consent for both the procedure and the sedation obtained and documented (verbal/written, or best-interests basis documented if the patient lacks capacity)
- Monitoring equipment attached and functioning: pulse oximetry, ECG/cardiac monitor, non-invasive blood pressure, capnography
- Documentation started (indication, planned sedation level, drugs planned, baseline observations)
- Time-out immediately before administering any drug: confirm correct patient, procedure, consent, allergies, monitoring attached, equipment checked and all team members ready
4 Β· Monitoring During Sedation
- Continuous pulse oximetry throughout, from before the first dose until the patient is back to baseline
- Respiratory rate and pattern/work of breathing observed continuously β do not rely on pulse oximetry alone, as hypoventilation can precede desaturation, especially with supplemental oxygen in use
- Capnography (ETCOβ): strongly recommended for moderate and deep sedation β it detects hypoventilation and apnoea earlier than pulse oximetry, particularly important when supplemental oxygen may mask falling saturations
- Blood pressure at least every 3β5 minutes, or continuously if clinically indicated
- Heart rate and ECG continuous monitoring; obtain a 12-lead ECG when clinically indicated by the patient's history or the procedure (e.g. cardioversion)
- Level/depth of sedation reassessed regularly β sedation is a continuum and a patient can drift from the intended level to a deeper one without warning
- Oxygen supplementation: apply according to local policy and clinical need β be aware supplemental oxygen can delay recognition of hypoventilation on pulse oximetry alone, reinforcing the value of capnography
- Frequency of observations: continuous monitoring during the procedure, with vital signs and conscious level formally recorded pre-procedure, at regular intervals (e.g. every 5β15 minutes) during, and post-procedure until the patient returns to baseline
- Recognise early: hypoventilation (reduced respiratory rate/depth), apnoea, airway obstruction (paradoxical chest movement, snoring, absent breath sounds), hypoxia (falling SpOβ) and hypotension β these can occur rapidly and require immediate action (section 9)
5 Β· Sedation Depth: A Continuum
- Minimal sedation (anxiolysis): patient responds normally to verbal commands; cognitive function/coordination may be impaired; ventilatory and cardiovascular function unaffected
- Moderate sedation and analgesia: patient responds purposefully to verbal commands, alone or with light touch; no intervention needed to maintain a patent airway; spontaneous ventilation adequate; cardiovascular function usually maintained
- Deep sedation and analgesia: patient cannot be easily roused but responds purposefully to repeated or painful stimulation; may need assistance maintaining a patent airway and adequate ventilation; cardiovascular function usually maintained
- General anaesthesia: patient is unrousable even to painful stimulation; airway and ventilatory support are often required; cardiovascular function may be impaired
- Dissociative sedation (ketamine): a distinct trance-like, cataleptic state with profound analgesia and amnesia, in which airway reflexes, spontaneous respiration and cardiopulmonary stability are usually preserved β it does not sit on the same continuum as the other levels and does not follow a simple dose-response relationship (there is a threshold dose for dissociation; further doses maintain rather than deepen the state)
- Key safety point: sedation exists on a continuum and patients can unintentionally progress to a deeper level than planned β the planned level should be decided in advance, and any deviation (intentional or not) should be recognised and documented
6 Β· Drugs for Adult Procedural Sedation
- PROPOFOL β class: phenol derivative/GABA-agonist, sedative-amnestic, no analgesic effect. Indications: sedation/amnesia, often combined with an opioid for painful procedures. IV dose: 0.5β1.0 mg/kg initial, given slowly; repeat 0.5 mg/kg every 3β5 minutes titrated to effect. Elderly/frail: initial dose as low as 10β20 mg, given slowly, with reduced repeat doses β reduce significantly in patients who are debilitated or have decreased cardiac function. Onset: Β½β1 min. Duration/peak effect: 1β2 min, short-acting. Adverse effects: hypotension, respiratory depression, pain on injection. Contraindications/precautions: known allergy to egg/soya lecithin (present in the formulation), caution in hypotension/hypovolaemia. Interactions: additive respiratory depression/hypotension with opioids and benzodiazepines. Elderly/frail: use lower initial doses, slower administration, longer intervals between top-ups. Renal/hepatic impairment: no dose adjustment required for a single procedural sedation episode, but effects may be prolonged in significant hepatic impairment. Key safety point: no analgesic or antiemetic effect β combine with an opioid or use with a technique providing analgesia for painful procedures.
- KETAMINE β class: phencyclidine derivative, dissociative anaesthetic with analgesic, sedative and amnestic properties. Indications: dissociative sedation for painful/traumatic procedures; sub-dissociative doses for analgesia alone. IV dose: 1β1.5 mg/kg given over 30β60 seconds (some sources: 10β30 mg lower fixed dose reasonable in the elderly); sub-dissociative analgesic dose 0.3 mg/kg IV. IM dose: 4β5 mg/kg, repeat with 2β2.5 mg/kg after 5β10 minutes if needed. Onset: Β½β1 min IV (slightly longer IM). Duration/peak effect: 1β2 min to peak effect; dissociation typically lasts 10β20 minutes after a single dose. Adverse effects: tachycardia, hypertension, laryngospasm (uncommon but serious β section 9), hypersalivation, nausea and vomiting, unpleasant emergence reactions/hallucinations (reduced by pre-treatment or co-treatment with a benzodiazepine), raised intracranial and intraocular pressure. Contraindications: age under 3 months (absolute), known or suspected schizophrenia (absolute); relative β known or suspected significant cardiovascular disease (including poorly controlled hypertension, angina, heart failure), active pulmonary infection/disease, CNS masses or hydrocephalus, globe injury or glaucoma. Elderly/frail: use lower end of dose range, titrate slowly. Renal/hepatic impairment: no specific dose adjustment established, use with caution and slower titration. Key safety point: does not follow a typical dose-response curve β there is a threshold dose for dissociation; prophylactic anticholinergics are not supported by evidence, and prophylactic benzodiazepine co-administration to reduce emergence reactions may benefit adults (evidence is limited) but is not proven to help in children.
- MIDAZOLAM β class: short-acting benzodiazepine, sedative-amnestic, no analgesic effect. Indications: sedation and amnesia, often combined with an opioid or used for anxiolysis. IV dose: 1β2 mg over 1β2 minutes (max single dose 2.5 mg), repeat after 2β5 minutes if needed. Elderly/frail: initial dose 0.5 mg, repeat 0.5 mg β use substantially lower doses than in younger adults. Onset: 1β2 min. Duration/peak effect: peak 3β4 min; accumulates in fat, which can significantly prolong sedation, especially in obese, elderly or hepatically/renally impaired patients. Adverse effects: respiratory depression, hypotension, paradoxical agitation/disinhibition (more common at low doses and in children/older adults). Contraindications/precautions: caution in hepatic/renal impairment and in the elderly (prolonged effect). Interactions: marked additive respiratory depression with opioids and other sedatives β this combination requires extra vigilance. Elderly/frail: substantially reduced doses as above. Renal/hepatic impairment: prolonged sedation likely β use lower doses and monitor for longer. Key safety point: no analgesic effect β give analgesia separately for painful procedures; the combination with opioids is a recognised high-risk combination for respiratory depression.
- FENTANYL β class: synthetic opioid, potent analgesic (approximately 72β125 times more potent than morphine by weight). Indications: analgesia, used with a separate sedative agent (e.g. propofol or midazolam) for painful procedures. IV dose: up to 0.5β1 mcg/kg initial, repeat 0.5 mcg/kg every 2 minutes titrated to effect; best given a few minutes before the sedative to maximise analgesic effect before the procedure starts. Onset: 1β2 min. Duration/peak effect: peak 3β5 min; clinical duration of effect roughly 30β60 min. Adverse effects: respiratory depression (potentiated significantly when combined with other sedatives, particularly propofol or midazolam), chest wall rigidity with rapid high-dose administration (rare at procedural sedation doses). Contraindications/precautions: caution in renal/hepatic impairment and the elderly, who may experience more profound or prolonged effects. Interactions: marked additive respiratory depression with any sedative-hypnotic β doses of no more than 0.5 mcg/kg are generally advised when combining with another sedation agent. Elderly/frail and renal/hepatic impairment: reduce dose and extend the interval between top-ups. Key safety point: the combination of an opioid with a sedative-hypnotic is more likely to cause respiratory depression than either drug alone β titrate slowly and monitor closely.
- ETOMIDATE β class: imidazole-derivative sedative-hypnotic, no analgesic effect. Indications: brief, painful procedure requiring deep sedation, particularly where haemodynamic stability is a priority (e.g. cardioversion in a haemodynamically borderline patient) β used less commonly for ED procedural sedation than for rapid sequence induction, and practice/familiarity varies between departments. IV dose: a low sub-induction dose is used for procedural sedation (typically a fraction of the induction dose used for intubation) β follow your local departmental protocol and use only if you are experienced with this specific application, as published adult procedural-sedation dosing is less standardised than for the other agents here. Onset: rapid (well under 1 min). Duration: very short (a few minutes). Adverse effects: pain on injection, myoclonus (can look like a seizure and interfere with the procedure), nausea/vomiting, adrenal suppression with repeated or prolonged dosing (less of a concern with a single procedural dose but still noted in current safety guidance). Contraindications/precautions: caution in sepsis/critical illness where adrenal suppression is a greater concern. Key safety point: myoclonus is common and can be mistaken for inadequate sedation or a seizure β warn the team in advance; this agent provides no analgesia, so combine with an appropriate analgesic for painful procedures.
- NITROUS OXIDE (Entonox / 50:50 nitrous oxide-oxygen) β class: inhaled gaseous agent, mild sedative-anxiolytic with some analgesic effect. Indications: minor procedures, anxiolysis, and as an adjunct for brief painful procedures in a cooperative patient who can self-administer via a demand valve/mouthpiece. Dose: patient self-administers by inhalation; no weight-based dose as it is titrated by the patient's own breathing pattern. Onset: very rapid (around 30 seconds). Duration: very short (around 1 minute after stopping), allowing rapid recovery. Adverse effects: nausea/vomiting, dizziness. Contraindications: pneumothorax, bowel obstruction, significant head injury with suspected reduced consciousness, sinus/middle-ear disease, and other closed gas-space pathology where the gas could expand. Key safety point: requires a well-ventilated room to prevent occupational exposure for staff, and requires the patient to be cooperative enough to self-administer.
- KETOFOL (ketamine + propofol, combined in the same syringe) β class: combination sedative-analgesic. Indications: procedural sedation, on the premise that combining lower doses of each drug reduces the individual side-effects (propofol's hypotension, ketamine's emergence/vomiting) while retaining efficacy. IV dose: 0.5β0.75 mg/kg of each agent, mixed 1:1 in the same syringe. Onset: Β½β1 min. Duration/peak effect: 1β2 min. Adverse effects: as for propofol and ketamine individually (hypotension, respiratory depression, emergence reactions, hypersalivation). Contraindications: as for propofol and ketamine individually β apply the more restrictive of the two agents' contraindications. Key safety point: current evidence has not shown ketofol to be clearly superior in safety or efficacy to either agent alone β use a combination you and your team are familiar with.
7 Β· Which Agent Should I Consider?
- This is a decision aid, not a rule β no single agent is universally superior; choice depends on the procedure, planned depth of sedation, patient factors, and the sedating clinician's training and familiarity with the agent
- Fracture/dislocation reduction (brief, very painful): ketamine (dissociative sedation) or ketofol are commonly favoured for their combined analgesia and sedation; propofol + a short-acting opioid (e.g. fentanyl) is a reasonable alternative if ketamine is contraindicated or not preferred
- Cardioversion (very brief, minimal analgesia needed): propofol alone is commonly used given its short duration and rapid recovery; etomidate is an alternative where haemodynamic stability is a particular concern, in departments familiar with this use
- Abscess incision/drainage or other moderately painful procedures: procedural sedation with local/regional anaesthesia where possible; propofol + fentanyl or ketamine are both reasonable depending on expected pain and duration
- Imaging or procedures requiring prolonged immobility: propofol (titratable, short-acting, allows control over depth) is often preferred; midazolam Β± an opioid is an alternative
- Very painful, longer procedures: ketamine or ketofol for their sustained analgesic and dissociative properties
- Agitated patient requiring a procedure: ketamine is often favoured as it preserves airway reflexes and spontaneous ventilation while providing dissociation; involve senior support early if there is diagnostic uncertainty about the cause of agitation
- Increased risk of respiratory depression (e.g. known OSA, morbid obesity, opioid-tolerant/naΓ―ve extremes): consider ketamine (preserves respiratory drive) over combinations of propofol/midazolam with opioids; if using the latter, use smaller increments with longer intervals and lower threshold for capnography
- Elderly/frail patients: reduce all initial doses substantially, give slowly, allow longer intervals between top-ups, and have a lower threshold for senior/anaesthetic support
- Significant cardiovascular disease: ketamine's sympathomimetic effect (tachycardia, hypertension) may be undesirable in significant ischaemic heart disease or poorly controlled hypertension; propofol's hypotensive effect may be poorly tolerated in haemodynamically borderline patients β choice should be individualised and discussed with a senior colleague if uncertain
8 Β· Administration Technique
Confirm the indication for the procedure and obtain informed consent for both the procedure and the sedation
β
Assess airway and overall sedation risk (section 2) and decide the planned sedation depth in advance
β
Prepare equipment and draw up/check all medications and reversal agents (section 3 checklist)
β
Establish full monitoring (pulse oximetry, ECG, blood pressure, capnography as indicated) before giving any drug
β
Perform a time-out immediately before administering the first dose, with the whole team present
β
Administer the chosen medication(s) using the doses in section 6
β
Titrate to the desired effect β use small incremental doses and allow adequate time between doses for peak effect before giving more
β
Perform the procedure once the target sedation depth is achieved
β
Continuously monitor throughout the procedure β do not become distracted by the procedure itself; the sedating practitioner's sole role is monitoring the patient
β
Manage any complication immediately using the stepwise approach in section 9
β
Begin structured recovery monitoring as soon as the procedure is complete (section 10)
9 Β· Sedation Emergencies
- General approach to any sedation emergency: Recognise β Stop/titrate down further sedative β Airway manoeuvres β Oxygen/support ventilation β Reversal agent where appropriate β Escalate/call for help and resuscitate
- Hypoxia: increase supplemental oxygen, ensure a patent airway (jaw thrust/chin lift), consider an airway adjunct; if not rapidly corrected, support ventilation with a bag-valve-mask and call for help
- Apnoea: stop further sedative administration, open the airway, support ventilation with a bag-valve-mask; give a reversal agent if an opioid/benzodiazepine is implicated (section 10); prepare for advanced airway management if apnoea persists
- Airway obstruction: reposition (jaw thrust/chin lift), suction secretions, insert an oropharyngeal/nasopharyngeal airway as tolerated; if obstruction persists, escalate to a supraglottic device or intubation
- Hypoventilation: stimulate the patient, reposition the airway, consider reducing/stopping further sedative, support ventilation as needed; capnography identifies this earlier than pulse oximetry alone
- Laryngospasm: stop the procedure immediately; apply firm, sustained pressure at 'Larson's point' (the laryngospasm notch, behind the ear lobe) with a jaw-thrust manoeuvre while delivering continuous positive airway pressure with 100% oxygen via bag-valve-mask; if saturations remain adequate, a small dose of propofol (e.g. 0.5 mg/kg IV) can deepen sedation and break the spasm; if desaturation continues despite this, proceed to a full-dose paralytic (e.g. suxamethonium 1.5 mg/kg IV or rocuronium 1.2 mg/kg IV) and prepare for intubation β ketamine-associated laryngospasm, though uncommon, is a recognised complication requiring immediate action
- Aspiration: suction the airway immediately, position appropriately (head-down/lateral if actively vomiting and not yet intubated), give supplemental oxygen, and prepare for intubation if there is ongoing risk or respiratory compromise
- Hypotension: give IV fluids, consider reducing/stopping further sedative, elevate the legs; escalate to vasopressor support and senior help if it does not respond promptly
- Bradycardia: treat the underlying cause (often hypoxia β correct this first), give anticholinergic treatment (e.g. atropine) per resuscitation guidelines if haemodynamically significant
- Arrhythmias: correct hypoxia and electrolyte disturbance, treat per standard resuscitation/arrhythmia protocols according to the specific rhythm and haemodynamic status
- Paradoxical agitation: more common with benzodiazepines, particularly in the elderly β ensure adequate oxygenation is not the cause of agitation first, reassure, and consider that further sedative may worsen rather than improve this reaction
- Vomiting: turn the patient to the lateral position if not protecting their own airway, suction as needed, treat with an antiemetic if the patient is stable and alert enough
- Emergence reactions (particularly with ketamine): keep the recovery environment calm and quiet with minimal stimulation; a benzodiazepine can be used to treat a significant reaction if it occurs, though routine prophylactic use to prevent this is not strongly evidence-based in adults
- Over-sedation: stop further drug administration, support airway/ventilation as needed, give a reversal agent if opioid/benzodiazepine-related, and extend monitoring until the patient returns to baseline
- Cardiopulmonary arrest: start immediate resuscitation per standard advanced life support guidelines, call for help/the resuscitation team, and continue until the patient responds or the team decides to stop
10 Β· Reversal Agents
- NALOXONE (opioid reversal) β Indication: opioid-induced respiratory depression/over-sedation. Dose: 0.1β0.2 mg IV titrated at 2β3 minute intervals to the desired degree of reversal (some departments use smaller increments, e.g. 40 mcg, when only reversal of respiratory depression β not full reversal of analgesia β is needed); IM administration gives a more prolonged effect if IV access is difficult. Repeat dosing: titrate to effect; further doses may be needed as some opioids (including fentanyl at higher/repeated doses) can outlast a single dose of naloxone. Precautions/warnings: use the smallest effective dose β an unnecessarily large dose can abruptly reverse analgesia and precipitate acute pain, agitation, hypertension and tachycardia; naloxone's duration of action may be shorter than the opioid's, so continue monitoring for re-sedation ('re-narcotisation') after apparent reversal.
- FLUMAZENIL (benzodiazepine reversal) β Indication: benzodiazepine-induced over-sedation/respiratory depression. Dose: 0.1β0.2 mg IV, repeated every minute as needed, to a maximum total dose of 2 mg. Repeat dosing/duration: re-sedation can occur (typically within around 90 minutes) as flumazenil's duration is shorter than many benzodiazepines, so further doses or extended monitoring may be required. Precautions/warnings: do not use in patients with a known seizure disorder, suspected co-ingestion of a pro-convulsant/sodium-channel-blocking agent, or known/suspected benzodiazepine dependence β reversing the benzodiazepine in these situations can precipitate seizures that may be difficult to control; only administer where the team is fully prepared to manage a seizure.
11 Β· Recovery, Aftercare & Safe Discharge Criteria
- Recovery monitoring: continue full monitoring in the same clinical area (with the same staffing/facilities available as during the procedure) until formal discharge criteria are met
- Airway and respiratory assessment: confirm a patent airway, normal respiratory rate/pattern and oxygen saturation without needing support
- Consciousness/mental status: confirm return to the patient's baseline level of alertness and orientation
- Cardiovascular observations: confirm heart rate and blood pressure have returned to baseline/normal ranges
- Pain and nausea: assess and treat before discharge β adequate analgesia and antiemetic treatment as needed
- Return to baseline neurological status: confirm no new or ongoing neurological deficit related to the sedation
- Safe Discharge Criteria β ALL of the following before discharge: vital signs at baseline/normal Β· airway patent with intact protective reflexes and no risk of reduced consciousness Β· nausea, vomiting and pain adequately addressed Β· return to baseline mental status/GCS Β· no unresolved adverse event or ongoing concern Β· follow-up arranged as required Β· safety-netting advice (and written information) given Β· accompanied home by a responsible adult if being discharged
- When admission/continued observation is required: any unresolved adverse event, failure to return to baseline within an expected timeframe, ongoing analgesia/antiemetic requirement not manageable as an outpatient, or any other clinical concern
12 Β· Discharge Advice
- Driving: advise the patient not to drive for at least 24 hours after sedation, or longer per local policy/the specific agent(s) used
- Alcohol: avoid alcohol for at least 24 hours β it can potentiate residual sedative effects
- Operating machinery: avoid operating machinery or performing potentially hazardous tasks for at least 24 hours
- Important decisions: avoid signing legal or financial documents or making significant decisions for 24 hours, as judgement/memory may still be affected
- Work/school: advise taking the rest of the day off; return the following day is usually reasonable if fully recovered
- Adult supervision: the patient should be accompanied home and supervised by a responsible adult for the remainder of the day
- Expected residual effects: mild drowsiness, unsteadiness or grogginess can persist for several hours; ketamine in particular can cause vivid dreams or mild disorientation into the following day for some patients
- When to seek medical attention: worsening drowsiness, difficulty breathing, chest pain, severe or worsening pain at the procedure site, persistent vomiting, or any new concerning symptom
13 Β· Documentation Checklist
- β Indication for the procedure and sedation
- β Consent (procedure and sedation)
- β Pre-sedation assessment (history, allergies, medications, fasting status, previous anaesthetic/sedation issues)
- β ASA physical status
- β Airway assessment (e.g. LEMON, Mallampati)
- β Drugs and doses given, including route and exact timing of each dose
- β Monitoring used and observations recorded at appropriate intervals
- β Planned and achieved sedation depth
- β Procedure performed and outcome
- β Any adverse events and interventions required
- β Recovery observations until baseline reached
- β Discharge assessment against safe discharge criteria
- β Discharge instructions given (verbal and written) and follow-up arranged
14 Β· Safety Warnings
- This is a clinical decision-support tool, not a substitute for local policy, training or clinical judgement β use it alongside your department's own procedural sedation policy and current guidance
- Procedural sedation requires practitioners with appropriate airway and resuscitation skills, and the equipment and staffing to manage a sedation-related emergency, regardless of which agent is chosen
- Respiratory depression and loss of airway reflexes can occur at any planned sedation depth β sedation is a continuum and patients can move to a deeper level than intended without warning
- No single drug or technique is universally appropriate β the right choice depends on the procedure, the patient and the sedating clinician's training and familiarity with the agent
- Combining an opioid with a sedative-hypnotic (e.g. fentanyl with propofol or midazolam) meaningfully increases the risk of respiratory depression compared with either drug alone β use smaller increments and extra vigilance
- This protocol covers adult dosing only β do not apply any of these doses to paediatric patients
- Doses are given in standard units (mg, mg/kg, mcg/kg) as specified for each drug β double-check units carefully when calculating a weight-based dose
- Where current guidance and local practice may differ (for example, exact ASA cut-offs for ED-suitability, or specific reversal-agent increments), this is noted in the relevant section β follow local policy where it is more conservative than stated here